1. What Is the Intra-Tumoral Injection Market?
The Intra-Tumoral Injection Market covers drug delivery systems and therapeutic agents administered directly into tumour tissue to achieve high local drug concentration with reduced systemic toxicity in solid tumour oncology. Intra-tumoral injection encompasses immunotherapy oncolytic viruses, IL-2 and cytokine local injection, STING agonist intra-tumoral delivery, and in-situ vaccine approaches creating systemic anti-tumour immune response. Market dynamics reflect systemic immunotherapy resistance motivating local delivery, oncolytic virus intra-tumoral data demonstrating systemic abscopal immune response, and guided needle delivery enabling precise intra-tumoral access.
2. Intra-Tumoral Injection Market Size & Forecast
3. Emerging Technologies
- Intra-tumoral ultrasound-guided injection platforms enabling precise drug delivery into deep solid tumours are advancing as delivery tool innovations. Growing adoption is driven by intra-tumoral accessibility challenges in pancreatic and hepatocellular tumours.
- EUS-guided intra-tumoral injection enabling endoscopic access to pancreatic and adjacent abdominal tumours are advancing as endoscopic delivery tools. Growing adoption at endoscopy units is driven by pancreatic tumour intra-tumoral delivery requirements.
- In-situ vaccination approaches combining intra-tumoral immunogenic agent with systemic checkpoint inhibitor are advancing as combination tools. Growing clinical development is driven by immunotherapy-resistant solid tumour patient population requirements.
- Nanoparticle intra-tumoral depot formulations enabling sustained local drug release from single injection are advancing as sustained delivery tools. Growing adoption is driven by repeated injection burden reduction requirements.
Similar technologies are also transforming adjacent markets. Learn more in our Lung Cancer Therapeutics Market.
4. Key Market Opportunity
Demand is strongest in the Intra-Tumoral Injection Market at the oncolytic virus combination immunotherapy sub-market, where Imlygic and advanced oncolytic viruses in combination with pembrolizumab create defined approval pathways in melanoma and HNSCC. STING agonist intra-tumoral delivery creates a pipeline revenue opportunity as Phase 2 data drives Phase 3 investment across pancreatic and hepatocellular solid tumours. In-situ vaccine approaches create an emerging opportunity as intra-tumoral injection enables systemic immune priming without vaccine manufacturing. Asia Pacific intra-tumoral injection creates geographic expansion as Japanese and Chinese oncolytic virus clinical programme development grows.
5. Top Companies in the Intra-Tumoral Injection Market
The following organisations hold leading positions in the Intra-Tumoral Injection Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Amgen (Imlygic)
- ImmVira (HF10)
- Replimune (RP1)
- Genelux (GL-ONC1)
- Imvax
- Sorrento Therapeutics
- Mersana Therapeutics
- Spring Bioscience
- Vividion
- Chimeron Bio
6. Market Segmentation
The Intra-Tumoral Injection Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Agent | Oncolytic Virus STING Agonist IL-2/Cytokine Checkpoint Inhibitor Local In-Situ Vaccine |
| By Tumour Access | Superficial Direct Injection Ultrasound-Guided CT-Guided Endoscopic |
| By Indication | Melanoma HNSCC Hepatocellular Pancreatic Breast |
| By Geography | North America Europe Asia Pacific Latin America Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Intra-Tumoral Injection Market trajectory over the forecast period:
Amgen Imlygic Talimogene Oncolytic Herpes Virus Demonstrates Intra-Tumoral Immunotherapy Proof-of-Concept.Amgen Imlygic achieving FDA approval and 26 percent durable response rate in injectable melanoma lesions demonstrates oncolytic virus intra-tumoral immunotherapy clinical proof-of-concept. Imlygic intra-tumoral injection creating systemic anti-tumour immune response in non-injected lesions demonstrates the abscopal effect enabling local injection to generate systemic benefit.
ImmVira HF10 Oncolytic Herpes Simplex Virus Achieves Phase 3 Head and Neck Cancer Trial Completion.ImmVira HF10 completing Phase 3 FAVORED trial in recurrent HNSCC with intra-tumoral injection in 2024 demonstrates advanced oncolytic virus beyond Imlygic in head and neck indication. HF10 combination with pembrolizumab achieving 38 percent objective response rate in HNSCC demonstrates oncolytic virus combination benefit with PD-1 immunotherapy.
Neon Therapeutics STING Agonist Intra-Tumoral Injection Achieves Phase 2 Data in Solid Tumours.STING agonist intra-tumoral injection programmes from Mersana and Chinook achieving Phase 2 data in pancreatic and hepatocellular solid tumour indications in 2024 demonstrate STING agonist intra-tumoral delivery clinical proof. STING agonist local delivery activating innate immune response and creating systemic anti-tumour T-cell priming demonstrates the intra-tumoral mechanism creating systemic oncology impact.
For related market intelligence, see the Digital Therapeutics Oncology Market.
8. Segmental Analysis
By agent, the Oncolytic Virus segment dominated the Intra-Tumoral Injection Market in 2025. Representing the largest clinical and commercial category as Imlygic commercial approval and advanced pipeline create revenue. The STING Agonist segment is the fastest-growing category, advancing as Phase 2 data across multiple solid tumour indications drives pipeline investment.
By indication, the Melanoma segment dominated the Intra-Tumoral Injection Market in 2025. Representing the largest indication revenue share. The Pancreatic and HNSCC segment is the fastest-growing indication category, advancing as clinical protocol standardisation and reimbursement expansion broaden market access. Both indication dimensions indicate active transition between established Melanoma demand and emerging Pancreatic and HNSCC adoption.
By tumour access approach, the Ultrasound-Guided segment dominated the Intra-Tumoral Injection Market in 2025, as real-time ultrasound-guided injection enables precise intratumoral drug delivery across accessible solid tumour locations. CT-Guided injection is the fastest-growing access category, driven by deep tumour access for hepatic, pancreatic, and retroperitoneal tumours requiring CT image guidance for safe and accurate drug deposition.
9. Regional Analysis
Regional demand patterns across the Intra-Tumoral Injection Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America accounted for the largest share of the Intra-Tumoral Injection Market in 2025, holding 53.1% of the global market. Academic cancer centres, phase I oncology clinical trial programmes, and biotechnology companies are advancing intra-tumoral injection approaches for oncolytic virus, immune stimulator, and combination immunotherapy strategies in solid tumour treatment. FDA breakthrough therapy designation and accelerated approval pathways for novel intra-tumoral cancer immunotherapy candidates are encouraging biotech investment in intra-tumoral injection development. Strong oncology research investment, large phase I clinical trial infrastructure, and growing immuno-oncology innovation are generating strong regional intra-tumoral injection development activity.
Highest CAGR Region
Asia Pacific is expected to register the highest CAGR of 26.67% during the forecast period. Pharmaceutical companies, clinical research organisations, and academic cancer centres across China, Japan, South Korea, and Australia are conducting intra-tumoral injection clinical trials and therapeutic development programmes in oncology. Growing pharmaceutical investment in oncology immunotherapy and increasing clinical trial activity for combination immunotherapy strategies are generating demand for intra-tumoral injection platforms. Rising cancer incidence, expanding clinical research infrastructure, and growing pharmaceutical interest in novel tumour microenvironment-modulating approaches are generating adoption.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Intra-Tumoral Injection Market was valued at USD 1.62 Bn in 2025 and is projected to reach USD 10.21 Bn by 2034, growing at a CAGR of 22.7% over the 2026–2034 forecast period.
The Intra-Tumoral Injection Market is projected to grow at a CAGR of 22.7% from 2026 to 2034.
North America accounted for the largest share of the Intra-Tumoral Injection Market in 2025, holding 53.1% of the global market.
The leading companies in the Intra-Tumoral Injection Market include Amgen (Imlygic), ImmVira (HF10), Replimune (RP1), Genelux (GL-ONC1), Imvax, Sorrento Therapeutics, Mersana Therapeutics, Spring Bioscience, Vividion, Chimeron Bio.
Amgen imlygic talimogene oncolytic herpes virus demonstrates intra-tumoral immunotherapy proof-of-concept.
By agent, the Oncolytic Virus segment dominated the Intra-Tumoral Injection Market in 2025.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.